[HTML][HTML] Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies …
FH Hu, YJ Jia, DY Zhao, XL Fu, WQ Zhang… - Clinical Microbiology …, 2023 - Elsevier
Abstract Background Although the SARS-CoV-2 Omicron variant is considered to induce
less severe disease, there have been no consistent results on the extent of the decrease in …
less severe disease, there have been no consistent results on the extent of the decrease in …
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic
A Zaccardelli, ZS Wallace… - Current opinion in …, 2023 - journals.lww.com
Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal …
Background Concerns have been raised regarding the reduced immunogenicity of vaccines
against COVID-19 in patients with autoimmune diseases treated with rituximab. However …
against COVID-19 in patients with autoimmune diseases treated with rituximab. However …
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …
Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies
EG Oakes, E Dillon, KA Buhler, H Guan, M Paudel… - Journal of …, 2024 - Elsevier
Objective Autoantibodies and autoimmune diseases after SARS-CoV-2 infection are widely
reported. Given evolving variants, milder infections, and increasing population vaccination …
reported. Given evolving variants, milder infections, and increasing population vaccination …
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 …
J Yazdany, A Ware, ZS Wallace, S Bhana… - Arthritis Care & …, 2024 - Wiley Online Library
Objective Approximately one third of individuals worldwide have not received a COVID‐19
vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among …
vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among …
Omicron variant infection in inflammatory rheumatological conditions–outcomes from a COVID-19 naive population in Aotearoa New Zealand
J Brooks, A Montgomery, N Dalbeth… - The Lancet Regional …, 2023 - thelancet.com
Background Due to geographic isolation and border controls Aotearoa New Zealand (AoNZ)
attained high levels of population coronavirus disease-19 (COVID-19) vaccination before …
attained high levels of population coronavirus disease-19 (COVID-19) vaccination before …
Older age, a high titre of neutralising antibodies and therapy with conventional DMARDs are associated with protection from breakthrough infection in rheumatoid …
Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs)
in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) …
in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) …
Efficacy and safety of anti-SARS-CoV-2 antiviral agents and monoclonal antibodies in patients with SLE: a case-control study
GA Ramirez, M Gerosa, C Bellocchi, D Arroyo-Sánchez… - Biomolecules, 2023 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-
19) has spread pandemically with high rates of morbidity and mortality. COVID-19 has also …
19) has spread pandemically with high rates of morbidity and mortality. COVID-19 has also …
Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic …
Y Yamaguchi, S Nameki, Y Kato, R Saita… - The Lancet Regional …, 2023 - thelancet.com
Background Autoimmune inflammatory rheumatic disease (AIRD) patients are at high risk of
the coronavirus disease 2019 (COVID-19), but the medium-term effects of …
the coronavirus disease 2019 (COVID-19), but the medium-term effects of …